SkinHealth Systems Inc.

What they do

SkinHealth Systems sells hydradermabrasion delivery systems (devices) and proprietary consumables (tips, solutions, serums) used in Hydrafacial treatments. The company also offers complementary products including SkinStylus microneedling and HydraScalp powered by Keravive. Its primary revenue comes from recurring consumables used by an installed base of providers worldwide.

Revenue drivers

• Consumables — Single-use tips, solutions, and serums used in Hydrafacial treatments; recurring revenue stream. Q2 2026 net sales were $53.9 million, down from $55.8 million in Q2 2025.
• Delivery Systems — Device sales (Syndeo, Elite Tower, Allegro) to providers; Q2 2026 net sales were $18.3 million, down from $22.4 million in Q2 2025, with 770 units placed versus 957 in the prior year.

Recent performance

For Q2 2026, total net sales were $72.1 million, down 7.8% year-over-year, with both delivery systems and consumables declining. Gross margin improved to 68.4% from 62.8%, and adjusted EBITDA rose to $17.0 million from $13.9 million. Net loss was $(2.7) million versus net income of $19.7 million in Q2 2025, which included an $18.1 million gain from debt exchange/repurchases. Active install base was 36,516 devices, up from 35,193 a year earlier.

Strategy

Management is focused on strengthening the core Hydrafacial franchise, increasing productivity of the installed base, and expanding the portfolio with complementary technologies. Priorities include selling and placing delivery systems worldwide, driving consumables, investing in provider and consumer communities, advancing the product pipeline, and optimizing global infrastructure. The company also plans to manage cost pressures through pricing actions, value engineering, and supplier diversification.

Risks

• Competitive pressure — The beauty health industry is highly competitive with large multinational companies and new disruptor brands, which could pressure pricing and market share.
• Macroeconomic headwinds — Inflation, recession, interest rates, and tariffs could impact customer financing, material costs, and demand.
• Syndeo issues — Problems with older Syndeo models and remediation actions could affect sales and customer trust.
• Debt and liquidity risk — The company has $363.4 million in long-term debt; availability of cash for debt service and default risk are noted concerns.

Outlook

Management provided Q3 2026 guidance of net sales between $65 and $70 million and adjusted EBITDA between $5 and $7 million. They expect continued sales pressure but anticipate improved gross margin from cost discipline and higher-margin consumables. The company aims to deliver sustainable, diversified long-term growth through its existing franchise, provider network, and recurring consumables model.